Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-04-05

Clinical Trial Update: A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males [Phase 2]

View source ↗

Summary

Phase 2 trial update for setipiprant tablets in male androgenetic alopecia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Setipiprant (setipiprant)

Snippet

Sponsor: Allergan | Conditions: Alopecia | Phase 2 | Status: COMPLETED | Results posted: 2019-04-05